Search

everythinglearnresearchcommunity

for

Search:↓

PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.

Adults with classic congenital adrenal hyperplasia value medication that prevents weight gain from glucocorticoids the most.

Hair loss linked to higher heart disease risk in both men and women.

Genetic mutations cause various hair diseases, and whole genome sequencing may reveal more about these conditions.

Aluminum foil packaging kept the biotin nutrition bar with the least bacteria after 30 days.

Insulin resistance and obesity are key factors in the development and worsening of polycystic ovary syndrome, and lifestyle changes are important for managing it.

Most people in Turkey start getting gray hair around 33 years old, with factors like age, education, hair loss, skin type, family history, and anxiety playing a role.

Hair loss may indicate a higher risk of heart disease and other health issues related to metabolism.

Polycystic Ovary Syndrome (PCOS) is not very common among Iranian women, but it's important to prevent it because of the risk of heart disease and infertility.

Hair loss links to higher death risk from diabetes and heart disease; not a direct cause, but a marker for risk factors.

Oral minoxidil promotes hair growth but may cause side effects; needs monitoring.

A new liposomal formulation improves drug delivery and hair growth for treating hair loss without causing skin irritation.

Low-dose oral minoxidil effectively promotes hair growth but has associated risks.

Prediabetes may be a risk factor for hair loss.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Men with genetic hair loss are more likely to have abnormal blood lipid levels, especially if the hair loss is severe.

Women with nonclassic congenital adrenal hyperplasia experience more sexual dysfunction and distress.

High fasting insulin levels in women with PCOS are linked to a higher risk of heart and metabolic problems.

Nanotechnology in dermatology shows promise for better drug delivery and treatment effectiveness but requires more safety research.

Testosterone therapy is beneficial for women's health and does not cause masculinization or liver damage, and it protects the heart and breasts.

The gene NM_026333 slows down aging by affecting the NCX1 pathway and could be targeted for anti-aging treatments.

Hair loss in middle-aged women is often linked to insulin resistance and a family history of hair loss, particularly from their fathers.

Pericardiocentesis and immunosuppressants effectively treat cardiac tamponade in pregnant women with SLE.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

The Modified Wash Test is reliable for diagnosing hair loss conditions and determining treatment priority.

The bulletin provides guidelines for diagnosing and managing PCOS, suggesting weight loss, hormonal contraceptives, and diabetes screening, with clomiphene for infertility and various treatments for excess hair.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.

The conclusion suggests a new treatment for infantile hemangiomas and a potential target for hair loss treatment.